Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

33.2K
Overview
33.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Comparison of candidate vaccines against Tick-borne encephalitis based on mRNA, simian adenovirus serotype 25 and a chimeric replication-competent yellow fever vaccine strain].

Voprosy virusologii·2026
Same author

The Mengla virus (<i>Filoviridae: Dianlovirus</i>).

Voprosy virusologii·2026
Same author

Virus taxonomy and megataxonomy (Vira domain) - current status.

Voprosy virusologii·2025
Same author

Genetic characteristics of the isolate of human adenovirus type 55 (<i>Adenoviridae: Mastadenovirus</i>) isolated in Moscow in 2022.

Voprosy virusologii·2025
Same author

[Bombali virus (Filoviridae: <i>Orthoebolavirus: Orthoebolavirus bombaliense</i>)].

Voprosy virusologii·2025
Same author

[Characteristics of the epidemic process of measles, rubella and mumps in Moscow and assessment of their seroprevalence at the present stage].

Voprosy virusologii·2025

Related Experiment Video

Updated: Feb 19, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K

Virus-Vectored Ebola Vaccines.

I V Dolzhikova1, E A Tokarskaya1, A S Dzharullaeva1

  • 1Federal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Gamaleya Str. 18, Moscow, 123098, Russia.

Acta Naturae
|November 7, 2017
PubMed
Summary
This summary is machine-generated.

Ebola virus disease (EVD) vaccines have advanced significantly, with virus-vectored options showing high efficacy in trials. This review details their development and immune response mechanisms for long-term protection.

Keywords:
Ebola vaccinesEbola virusrecombinant viral vectorsvirus-vectored vaccines

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K
Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice
10:01

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

8.5K

Related Experiment Videos

Last Updated: Feb 19, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K
Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice
10:01

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

8.5K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Ebola virus disease (EVD) is a severe zoonotic infection with a high fatality rate.
  • Over 20 EVD outbreaks have occurred since 1976, including a major epidemic in West Africa (2014-2016).
  • Limited vaccine availability hindered early epidemic response, highlighting the need for effective EVD vaccines.

Purpose of the Study:

  • To review the technological advancements in EVD vaccine development.
  • To focus on virus-vectored Ebola vaccines evaluated in preclinical and clinical trials.
  • To examine immune response mechanisms and parameters for long-term EVD protection.

Main Methods:

  • Review of scientific literature on Ebola virus disease vaccine development.
  • Analysis of preclinical and clinical trial data for virus-vectored vaccines.
  • Examination of immunological mechanisms underlying vaccine-induced protection.

Main Results:

  • Virus-vectored vaccines have shown significant efficacy in preclinical studies.
  • Several EVD vaccine candidates are progressing through clinical trials.
  • Understanding immune response pathways is crucial for vaccine effectiveness.

Conclusions:

  • Virus-vectored vaccines represent a promising strategy for EVD prevention.
  • Continued research into immune responses is vital for optimizing vaccine design.
  • Development of licensed EVD vaccines is critical for global health security.